Videos

Downloads

MHC Associated Peptide Proteomics

Case Study MAPPs for Vaccine Design To identify MHC class I presented antigens derived from influenza strain H1N1, two[...]

Download

iTope™ and TCED™ Fact Sheet

More information on Abzena’s iTope™ and TCED™ technology including a detailed look at the results.

Download

EpiScreen™ Time Course T Cell Assay Fact Sheet

More information on the EpiScreen™ time course T cell assay and a case study showing the potential immunogenicity[...]

Download

Events

References

A comparison of the ability of the human IgG1 allotypes G1m3 and G1m1,17 to stimulate T-cell responses from allotype matched and mismatched donors.

Carl I. Webster, Christine J. Bryson, Edward A. Cloake, Tim D. Jones, Mark J. Austin, Anette C. Karle, Sebastian[...] Read more

Small Amounts of Sub-Visible Aggregates Enhance the Immunogenic Potential of Monoclonal Antibody Therapeutics

Maryam Ahmadi, Christine J. Bryson, Edward A. Cloake, Katie Welch, Vasco Filipe, Stefan Romeijn, Andrea Hawe, Wim[...] Read more

Drug Discovery Tutorial: Detection and Reduction of Immunogenicity

Drug Discovery Tutorial: Detection and Reduction of Immunogenicity This article discusses how early removal of T-cell[...] Read more

Assessing Immunogenicity Using Ex Vivo T cell Assays

Assessing Immunogenicity Using Ex Vivo T cell Assays This article discusses Antitope’s developed highly sensitive ex[...] Read more

Pre-clinical considerations in the assessment of immunogenicity for protein therapeutics

Baker M, Carr F. Curr Drug Saf. 2010 Oct;5(4):308-13. Abstract Protein therapeutics offer distinct advantages over other[...] Read more

Immunogenicity of protein therapeutics The key causes, consequences and challenges

Matthew P. Baker,* Helen M. Reynolds, Brooke Lumicisi and Christine J. Bryson, Self/Nonself, Volume 1, Issue 4, 2010[...] Read more

Prediction of immunogenicity of therapeutic proteins: validity of computational tools.

BioDrugs. 2010 Feb 1;24(1):1-8. doi: 10.2165/11318560-000000000-00000. Bryson CJ, Jones TD, Baker MP. Abstract Most[...] Read more

In vitro screening for antibody immunogenicity

In book: recombinant antibodies for immunotherapy, Chapter: In vitro screening for antibody immunogenicity, Publisher:[...] Read more

New approaches to prediction of immune responses to therapeutic proteins during preclinical development.

Drugs R D. 2008;9(6):385-96. doi: 10.2165/0126839-200809060-00004, Perry LC, Jones TD, Baker MP. Abstract Clinical[...] Read more

Assessment of the immunogenicity of different interferon beta-1a formulations using ex vivo T-cell assays

J Pharm Biomed Anal. 2007 Mar 12;43(4):1256-61. Epub 2006 Nov 21. Jaber A, Baker M. Abstract Recombinant homologues of[...] Read more

News

Abzena Announces New Fully Integrated Developability and Optimization Service to Improve Lead Selection and De-risk Biologic Cell Line Development

Cambridge, UK 21 March 2019 – Abzena, the leading biologics target to GMP partner research organisation (PRO),[...] Read more

Abzena announces a research and licence agreement with Tmunity Therapeutics, a T cell engineering company

Cambridge, UK, 19 September 2018 – Abzena, plc (AIM: ABZA, Abzena’), the life sciences group providing services and[...] Read more

Interested in our services? Get In Touch